Deutsche Bank says Amgen’s (AMGN) MariTide’s Phase 2 press release “underwhelms” with 20% weight loss from Cohort A and 17% weight loss from Cohort B at 52-weeks, with it being unclear if these are placebo adjusted. MariTide’s weight loss appears to miss the Street’s bogey of 25% weight loss and will weigh down Amgen shares, the analyst tells investors in a research note. Amgen noted no weight loss plateau was seen at 52 weeks, which is encouraging, but may not be viewed as differentiated to next generation assets such as Eli Lilly’s (LLY) Triple G or Novo Nordisk’s (NVO) CagriSema, adds Deutsche Bank. The firm thinks Lilly shares should be up slightly on MariTide’s Phase 2 weight loss figures as Novo’s REDEFINE1 readout “still needs to wash out.” Deutsche has a Hold rating on Amgen with a $305 price target. The stock in premarket trading is down 12% to $259.01.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AMGN:
- Morning Movers: Dick’s Sporting jumps and Kohl’s sinks following earnings
- Amgen down 4% after reporting MariTide weight loss study results
- Amgen’s MariTide shows up to 20% average weight loss in Phase 2 study
- Eli Lilly, others to buy after RFK-inspired drop, Barron’s says
- Amgen appoints Howard Chang as SVP of Research and Chief Scientific Officer
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
